CEO Gunilla Osswald and CFO Anders Martin-Löf will lead the session, offering commentary on the company's results for the April to June period. The presentation includes a dedicated segment for questions, allowing investors, analysts, and media members to engage directly with the leadership team. Participants may submit written inquiries via the webcast portal or join a teleconference to pose questions verbally.

BioArctic, known for its work on the Alzheimer's treatment Leqembi, continues to advance its research portfolio, which includes projects targeting Parkinson's disease and ALS. The upcoming report will provide insight into these developments and the firm’s proprietary BrainTransporter technology. For those unable to attend the live event, a recording will be made available on the company’s investor relations website shortly after the broadcast concludes.